Skip to main content

Table 3 Serial changes in body weight, blood pressure, FPG, and HbA1c from baseline to the last follow-up visit

From: Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients

Variables

Mean difference

95% CI

p-value

Mean

SD

LL

UL

Weight; kg

Baseline & visit 1

0.02

3.05

-0.40

0.44

0.933

Baseline & visit 2

0.85

4.15

0.26

1.45

0.005*

Baseline & visit 3

1.12

4.18

0.52

1.73

0.000*

Hypertensive

SBP; mmHg

Baseline & visit 1

11.73

16.61

7.94

15.53

0.000*

Baseline & visit 2

12.31

16.69

8.36

16.26

0.000*

Baseline & visit 3

13.25

15.82

9.45

17.05

0.000*

DBP; mmHg

Baseline & visit 1

6.45

11.02

3.93

8.96

0.001*

Baseline & visit 2

5.25

8.56

3.23

7.28

0.003*

Baseline & visit 3

6.38

8.83

4.26

8.50

0.000*

Non-Hypertensive

SBP; mmHg

Baseline & visit 1

1.01

13.07

-1.24

3.26

0.377

Baseline & visit 2

3.46

12.00

1.31

5.61

0.002

Baseline & visit 3

3.30

13.05

0.93

5.67

0.007

DBP; mmHg

Baseline & visit 1

-0.02

9.51

-1.65

1.62

0.985

Baseline & visit 2

0.43

9.36

-1.25

2.10

0.616

Baseline & visit 3

0.96

10.12

-0.88

2.79

0.304

FPG; mg/dL

Baseline & visit 1

34.64

36.80

29.59

39.70

0.000*

Baseline & visit 2

39.76

33.77

34.95

44.58

0.000*

Baseline & visit 3

46.63

38.77

41.04

52.23

0.000*

HbA1c; %

Baseline & visit 2

0.94

0.71

0.83

1.04

0.000*

Baseline & visit 3

1.24

0.94

1.11

1.38

0.000*

  1. SBP-Systolic Blood Pressure; DBP-Diastolic Blood Pressure; HbA1c-Glycated Hemoglobin; FPG-Fasting Plasma Glucose; SD-Standard Deviation; LL-Lower Limit; UL-Upper Limit
  2. Paired Sample T-test is applied to observe the mean change in study variables from baseline to follow-up (for parametric data). *p < 0.05 is considered statistically significant